Lee Eun Mi, Kim Dong Hyun, Kim Do Young, Seol Young Mi, Choi Young Jin, Kim Hyojeong
Division of Hemato-oncology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Department of Radiation Oncology, Pusan National University School of Medicine, Busan, Korea.
Radiat Oncol J. 2018 Dec;36(4):325-331. doi: 10.3857/roj.2018.00262. Epub 2018 Dec 31.
Soft tissue sarcoma (STS) is a rare and heterogeneous cancer with over 50 known subtypes. It is difficult to understand the role of adjuvant treatment in STS. We aimed to determine the benefits of adjuvant treatment for a rare STS subset: non- extremity STS with moderate chemosensitivity.
We reviewed medical records from Pusan National University Hospital and Kosin University Gospel Hospital, which had detailed pathological reports on patients diagnosed between 2006 and 2016. The most important inclusion criterion was resection with curative intent. We grouped STS by chemosensitivity based on reported data and analyzed non- extremity STS with moderate chemosensitivity.
We investigated 142 patients with 20 pathological subtypes of STS. Eighty-six patients had extremity STS and 56 had non- extremity STS. Thirty-eight of 56 patients were categorized as having moderate chemosensitivity. Seventeen of 38 patients (44.7%) received adjuvant radiotherapy and 14 (36.8%) received adjuvant chemotherapy. A log-rank test showed longer disease-free survival (DFS) in the adjuvant radiotherapy group than in the group treated without adjuvant radiotherapy (not reached vs. 1.468 years, p = 0.037). Multivariate Cox proportional hazard analysis, with covariates including age, stage, resection margin, adjuvant chemotherapy, and adjuvant radiotherapy, revealed that adjuvant radiotherapy was associated with longer DFS (odds ratio = 0.369, p = 0.045). Overall survival was not correlated with adjuvant radiotherapy.
Adjuvant radiotherapy may be associated with longer DFS in patients with non-extremity STS with moderate chemosensitivity.
软组织肉瘤（STS）是一种罕见的异质性癌症，已知亚型超过50种。很难理解辅助治疗在STS中的作用。我们旨在确定辅助治疗对一种罕见的STS亚组的益处：具有中度化疗敏感性的非四肢STS。
我们回顾了釜山国立大学医院和高信大学福音医院的病历，这些病历对2006年至2016年间诊断的患者有详细的病理报告。最重要的纳入标准是根治性切除。我们根据报告的数据按化疗敏感性对STS进行分组，并分析具有中度化疗敏感性的非四肢STS。
我们调查了142例患有20种病理亚型STS的患者。86例患者患有四肢STS，56例患有非四肢STS。56例患者中有38例被归类为具有中度化疗敏感性。38例患者中有17例（44.7%）接受了辅助放疗，14例（36.8%）接受了辅助化疗。对数秩检验显示，辅助放疗组的无病生存期（DFS）长于未接受辅助放疗的组（未达到 vs. 1.468年，p = 0.037）。多变量Cox比例风险分析，协变量包括年龄、分期、切除边缘、辅助化疗和辅助放疗，显示辅助放疗与更长的DFS相关（优势比 = 0.369，p = 0.045）。总生存期与辅助放疗无关。
辅助放疗可能与具有中度化疗敏感性的非四肢STS患者更长的DFS相关。
